Loading But Tiba says it needs access to an mRNA manufacturing facility in Australia to make the vaccines at a commercial scale on our shores. The Moderna rejection has forced the company and the ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

Challenges such as declining vaccination rates and regulatory uncertainties for manufacturing plants in key markets like the UK, Canada, and Australia also impacts the company, with Moderna also ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people worldwide every year, and though there is currently no preventive vaccine ...

Moderna's revenue and stock price have steadily declined since global demand for COVID-19 vaccines has dwindled. During 2020 and 2021, the company generated massive revenues, fueled by its ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Investors should be aware of 2025 headwinds, including declining COVID-19 vaccine sales and potential regulatory impacts from RFK Jr.'s appointment. During the pandemic, Moderna took advantage of ...